Sida Cordifolia for Strength, Nerves and Rejuvenation: What Rasayana Claims Actually Trace To

The hub’s Rejuvenative and Strength Claims section already makes one sharp point: an adaptogen is supposed to calm the stress response, and ephedrine does the opposite, so grouping bala with ashwagandha on a supplement shelf is misleading. That is correct as far as it goes. This page goes further, because “strength” and “rejuvenation” are not one claim — bala’s Sanskrit name itself just means strength, and the classical tradition attaches that word to several different things: a subjective feeling of vigour, resistance to nerve and joint complaints, and recovery from illness or childbirth. Modern research, it turns out, has something to say about several of these independently of the stimulant alkaloid — and one surprising finding that cuts against the stimulant story directly.

The organising question of this page is the one the site’s evidence doctrine asks of every benefit claim on a plant with a documented hazard mechanism: does this specific claim trace back to the same alkaloid the hub already warns about, or to something else entirely? The honest answer, claim by claim, is mixed — and more interesting than either “it’s all just the stimulant” or “it’s all separately proven” would be.

Table of Contents

1. The Rasayana Framing
2. The One CNS Study Found the Opposite of “Energising”
3. Neuropathic Pain: A 2024 Mechanism Study, and It Is Not About Ephedrine
4. The First Human Trials in This Claim Area
5. Analgesic and Anti-Inflammatory Activity, Replicated Across Four Countries
6. “Strength,” Reframed: An Actual Bone Mechanism
7. Testing the Rasayana Claim on Its Own Terms
8. Convalescence and the Liver: Two Studies, Two Different Solvents
9. What Does Not Get a Pass
10. Sorting the Claims by Mechanism
11. Evidence Ledger for This Page
12. Key Research Papers
13. Connections

The Rasayana Framing

Evidence tier: traditional use, well-documented.

The hub’s Traditional Use section places bala among the balya (strength-giving) and vatahara (pacifying vata, the principle governing movement and the nervous system) drugs, used in musculoskeletal and neurological complaints, respiratory complaints, and general debility or convalescence. The classical preparations tell you what kind of claim this originally was: medicated oils rubbed onto joints and nerves (Bala taila, Ksheerabala taila) for “joint pain, muscle wasting, neuropathy and paralysis,” a fermented decoction (Balarishta) taken by the spoonful, and root simmered in milk (Ksheerapaka) as convalescent food. None of that is the language of a pre-workout stimulant. It is the language of a slow-acting tonic given to someone recovering from illness, injury or childbirth — which makes the modern “for energy and stamina” marketing a genuine departure from the classical framing, not merely a modern gloss on it.

The One CNS Study Found the Opposite of “Energising”

Evidence tier: animal, single study — and worth reporting exactly as it landed.

Only one dedicated study has examined this plant’s direct effect on the central nervous system, and its result runs against both the marketing and the naive “it contains ephedrine, so it must be stimulating” assumption. Franco and colleagues gave mice a hydroalcoholic extract of Sida cordifolia leaves and ran the standard psychopharmacology battery. At 1000 mg/kg (intraperitoneal), the extract produced a significant reduction in spontaneous motor activity and in ambulation and rearing on the open-field test, at 30, 60 and 120 minutes — a depressant, sedative-type profile, not a stimulant one (Franco CI et al., Journal of Ethnopharmacology, 2005).

Four things are worth saying about this finding, in the interest of reporting it accurately rather than either dismissing it or over-reading it:

• It is one study, in mice, by intraperitoneal injection, at a high dose of whole leaf extract — not oral dosing, not a human, not the isolated alkaloids. It cannot be generalised to “this plant is a sedative.”
• It used the leaf (aerial part), which the hub notes is the alkaloid-richer part used in modern extracts — so this is not a low-alkaloid preparation escaping the ephedrine story by using a different plant part.
• It genuinely contradicts the “energising tonic” marketing claim, which is exactly the kind of finding the site’s evidence practice asks to be reported rather than quietly dropped because it is inconvenient for the popular narrative.
• It also complicates a simple “it’s just the ephedrine” story. If the dominant CNS-active constituent were ephedrine acting as expected, a whole-leaf extract at a high dose would be expected to show stimulant, not depressant, behavioural signs. Either a non-alkaloid constituent (or a different alkaloid in the mixture) is dominating the behavioural result at this dose, or high-dose acute toxicity is producing a nonspecific sedative-looking effect that has nothing to do with any single named mechanism. The paper does not resolve which, and neither can we.

The honest summary: the single dedicated CNS pharmacology study on this plant found a depressant effect, not the stimulant one either the marketing or the cardiovascular-hazard framing would predict. That is a genuine contradiction in this plant’s file, and it belongs on the page rather than in a footnote.

Neuropathic Pain: A 2024 Mechanism Study, and It Is Not About Ephedrine

Evidence tier: animal, mechanistic, recent (2024) — the strongest alkaloid-independent finding on this page.

The classical tradition specifically credits bala root for neuralgia, sciatica and facial paralysis — the “neurological complaints” cluster the hub’s Traditional Use section names. A 2024 study gives that specific claim real modern support, through a mechanism that has nothing to do with ephedrine. Tiwari and Hemalatha extracted Sida cordifolia roots and tested the whole extract and its aqueous fraction in a rat model of chronic constriction injury — a standard, well-validated model of neuropathic pain. Both preparations produced a significant, dose-dependent reduction in mechanical and thermal hypersensitivity, and suppressed the molecular signature of nerve injury in the dorsal root ganglion and spinal cord: pro-inflammatory cytokines (TNF-α, IL-1β), glial activation markers, the neuropeptides CGRP and substance P, and — the specific mechanism the paper worked out — a signalling pathway called KIF17-mediated NR2B trafficking, part of the NMDA-receptor system that drives central pain sensitisation (Tiwari V, Hemalatha S, Journal of Ethnopharmacology, 2024).

Two details make this the cleanest “different compound, different mechanism” case on this page:

• It used the root — the traditional part, the low-alkaloid part per the hub’s own Overview section — not the alkaloid-rich aerial material.
• The active fraction’s major identified constituent was betaine, one of the “minor nitrogenous constituents” the hub’s Active Compounds section already lists — not ephedrine, not vasicine, and not an adrenergic or sympathomimetic mechanism at all. NMDA-receptor trafficking is a completely separate pharmacological system from the adrenoceptor pathway that drives the cardiovascular hazard.

This is the plant’s best example of the site’s doctrine that benefit and hazard sometimes come from genuinely different compounds, and when they do, that is decisive: a reader taking a root decoction for nerve pain is not, on this evidence, engaging the same mechanism that raises blood pressure. That does not make root material automatically safe — it still contains some ephedrine, and the hub’s general cautions still apply — but the analgesic claim itself does not stand or fall with the stimulant one.

The First Human Trials in This Claim Area

Evidence tier: one completed randomised placebo-controlled human trial (confounded by a co-administered herb), plus one registered single-agent trial protocol.

Unusually for this plant, the neurological and musculoskeletal claims are the one part of this Benefits leg where human trial evidence now exists — making this page’s earlier framing worth sharpening rather than leaving as “animal only.”

A 2022 randomised, partly double-blinded, placebo-controlled trial enrolled 90 patients with diabetic sensory polyneuropathy and tested two pharmaceutical forms — classical whole-drug powder versus a modern aqueous-alcoholic extract — of a combination of Phyllanthus niruri (whole powder) and Sida cordifolia (root decoction), against placebo. Both herbal forms produced a significant reduction, versus placebo, in the validated Neuropathy Total Symptom Score across aching pain, allodynia, burning pain, numbness and pricking pain, with no significant difference between the classical and modern preparation forms (Patel MV et al., Journal of Ayurveda and Integrated Medicine, 2022). This is genuine, positive, placebo-controlled human evidence in the same broad territory — nerve pain — as the Tiwari 2024 rat mechanism study above. It comes with the same caveat this site applies to every combination-product result: Phyllanthus niruri is itself a well-studied plant with its own antidiabetic and neuroprotective literature, and this trial cannot tell you how much of the benefit, if any, came from the Sida cordifolia component specifically rather than from its partner herb. Formula substitution applies here exactly as it does elsewhere on this site — but unlike most formula-confounded results, this one at least sits inside the correct claim territory (nerve pain) rather than a different indication entirely.

Separately, a 2025 trial protocol registered and now recruiting at an Indian Ayurvedic teaching hospital is testing Sida cordifolia oil, administered nasally (the classical nasya technique), as a genuinely single-agent arm against honey thermal microcautery and standard physiotherapy for frozen shoulder (adhesive capsulitis) — a joint condition, consistent with the “joint pain, muscle wasting” indication the classical medicated oils were used for. As of the published protocol, 16 of a planned 60 patients had been recruited, with results anticipated after the trial completes (Pathania S et al., JMIR Research Protocols, 2025). We have not found a completed-results publication from this trial as of this page’s writing; when one is published, it will be the first genuinely single-herb human trial outcome this plant has ever had.

Analgesic and Anti-Inflammatory Activity, Replicated Across Four Countries

Evidence tier: animal only, but independently replicated by unconnected research groups.

Beyond the specific neuropathic-pain mechanism above, general analgesic and anti-inflammatory activity is one of the most consistently replicated findings on this plant, across labs with no apparent connection to one another:

• Bangladesh: a new quinazoline alkaloid isolated from the whole plant reduced writhing, increased tail-flick latency and reduced carrageenan-induced paw oedema in a dose-dependent manner (Sutradhar RK et al., Pakistan Journal of Pharmaceutical Sciences, 2007 — the compound discussed on the respiratory page, chemically a vasicine relative, not ephedrine-type).
• India: ethyl acetate extracts of both root and aerial parts showed analgesic activity comparable to indomethacin, with the root extract additionally showing hypoglycaemic activity (Kanth VR, Diwan PV, Phytotherapy Research, 1999).
• Brazil: a leaf ethanol extract and its chloroform and methanol fractions reduced orofacial pain in the glutamate and formalin nociception tests, an effect that was partly reversed by naloxone — meaning part of the effect runs through the opioid system, a third mechanism distinct from both the quinazoline and NMDA pathways above (Bonjardim LR et al., Phytotherapy Research, 2011).
• Burkina Faso: aqueous acetone extracts of both Sida acuta and Sida cordifolia produced dose-dependent analgesia in the writhing and hot-plate tests, alongside a formal acute-toxicity assessment that put the intraperitoneal LD50 at 3.4 g/kg in mice (Konaté K et al., BMC Complementary and Alternative Medicine, 2012).

Four countries, four extraction methods, at least three distinct proposed mechanisms (a quinazoline alkaloid, an opioid-system interaction, and unspecified anti-inflammatory activity in the ethyl acetate work) converging on the same general finding is a genuinely more persuasive pattern than any single paper — though it remains, in every case, animal-only. No trial of this plant for the general writhing/paw-oedema style of pain and inflammation tested here exists in humans; the one human pain trial that does exist, discussed above, is specific to diabetic neuropathy and confounded by a co-administered herb.

Separately, and tested as an individual herb rather than inside a combination product, Sida cordifolia powder was one of six traditional anti-inflammatory herbs given alone (not as a formula) in a rat model of collagenase-induced osteoarthritis, and was one of two — alongside long pepper — that showed a protective effect on cartilage radiographically and histologically (Nirmal P et al., American Journal of Chinese Medicine, 2013). Because each herb was dosed as its own powder suspension rather than combined into one product, this is genuine single-herb evidence, not the formula-substitution problem that affects many combination-product claims elsewhere on this site.

“Strength,” Reframed: An Actual Bone Mechanism

Evidence tier: animal, mechanistic, recent (2022) — and almost never mentioned in marketing.

Here is the page’s sharpest reframing. Modern marketing for bala leans on “strength” as a synonym for stimulant energy — the hub already shows why that reading is mechanistically confused, since ephedrine drives a stress response rather than restoration. But there is a second, far more literal candidate for what “strength” could mean, and it has real, recent, non-alkaloid supporting data that the marketing does not use.

Patel and colleagues tested ethanolic extracts of both root and leaf in primary osteoblast culture and in ovariectomised mice — the standard model for postmenopausal bone loss. Both extracts increased osteoblast (bone-forming cell) proliferation, differentiation and mineralisation, activated the ERK, AKT and CREB signalling pathways, and shifted the OPG/RANKL ratio to favour bone formation over resorption. In the mice, both extracts improved trabecular and cortical bone microarchitecture — bone mineral density, bone volume fraction, trabecular number and thickness — measured by micro-CT, and improved vertebral bone mass on histology. The mechanism traced to the extracts’ polyphenol and flavonoid content and antioxidant activity, not to any alkaloid (Patel K et al., Phytomedicine, 2022).

This is, quite literally, a bone-strengthening mechanism — measured, dose-responsive, in the correct disease-relevant model, and running through the polyphenol fraction rather than ephedrine or the quinazolines. It is a stronger, more literal match for “bala” (strength) than the stimulant “energy” framing the shelf actually sells, and it appears not to have made it into commercial marketing at all — which is itself worth noting: the more mechanistically verifiable modern finding is the one nobody is using to sell the product.

Testing the Rasayana Claim on Its Own Terms

Evidence tier: animal/in vitro, and solvent-dependent — read the fine print.

Rasayana plants are specifically supposed to counter degenerative ageing, and the mechanism most often proposed for that whole drug class is antioxidant activity protecting neurons from oxidative damage. Auddy and colleagues tested this directly: they screened three Ayurvedic rasayana plants — Sida cordifolia, Evolvulus alsinoides and Cynodon dactylon — for antioxidant activity relevant to neurodegenerative disease, in both ethanolic extract and water infusion form. In the ABTS radical-scavenging assay, the Sida cordifolia ethanolic extract was the most potent of the three (IC50 16.07 µg/mL). In the water infusion — the form closer to a traditional decoction — it fell to last of the three (IC50 342.82 µg/mL) (Auddy B et al., Journal of Ethnopharmacology, 2003).

That solvent gap matters, and it is the same pattern this site has flagged on other herbs: a laboratory result obtained with an ethanol extract does not automatically transfer to the water-based preparation the tradition actually uses. The rasayana antioxidant claim has real support — but mainly for a concentrated ethanolic extract, and considerably less for the traditional decoction form, which is the honest, unflattering half of this result.

Convalescence and the Liver: Two Studies, Two Different Solvents

Evidence tier: animal only, but with a useful internal solvent contrast.

The classical Ksheerapaka preparation — root simmered in milk, given to convalescents — points at a general recovery/tonic claim rather than a specific organ target, but two independent lines of animal work have tested a liver-specific version of it.

Rejitha and colleagues gave rats a 50% ethanolic root extract alongside chronic alcohol dosing over 90 days, and found it significantly lowered every measured marker of alcohol-induced liver toxicity (ALT, AST, GGT, lipid peroxidation products, collagen deposition), restored antioxidant enzyme activity and glutathione, and reduced the inflammatory transcription factors (NF-κB, TNF-α) that alcohol had raised (Rejitha S et al., British Journal of Nutrition, 2012). A follow-up traced the mechanism specifically to Nrf2-mediated upregulation of glutathione metabolism (Rejitha S et al., Redox Report, 2015). Separately, an aqueous leaf extract — the solvent that actually matches a traditional preparation — increased liver regeneration (measured by proliferating-cell marker staining) after partial hepatectomy in rats, at low-to-moderate doses (Silva RL et al., Acta Cirúrgica Brasileira, 2006).

These are two different hepatic claims (protection against a toxic insult, and promotion of regeneration after injury), from two different labs, using two different extraction methods — and, usefully, the aqueous-extract result is the one that most resembles what a traditional decoction would deliver. Neither has been tested in humans, and neither should be read as license to drink bala instead of stopping alcohol or seeking care for liver disease. But as a candidate mechanism for the traditional “convalescent tonic” claim, the hepatic data is real, plural, and — like the bone and neuropathic-pain findings above — not obviously running through ephedrine.

What Does Not Get a Pass

None of the above should be read as clearing this plant’s “energising” and “vitality” marketing, which is precisely the claim that does trace back to the stimulant alkaloid, exactly as the hub already argues. The subjective sense of alertness or drive that a bala supplement produces is the expected pharmacology of a sympathomimetic amine acting on the central and autonomic nervous system — not a rejuvenative effect, and not, per the CNS study above, even reliably a stimulant one at the whole-extract level. If anything, this page’s findings sharpen the hub’s point rather than soften it: the specific claims with real, mechanistically distinct, alkaloid-independent modern support (nerve pain, bone density, hepatic and antioxidant activity) are exactly the ones the “energy tonic” marketing does not lead with.

Sorting the Claims by Mechanism

Collecting the whole page into one table of claim against mechanism:

• Traces to the stimulant alkaloid (ephedrine/pseudoephedrine) — covered on the hub, not cleared here: the subjective “energy,” “vitality” and stamina marketing claims.
• Genuinely independent of the stimulant alkaloid, with real modern mechanistic support: neuropathic pain and nerve-related complaints (betaine, NMDA pathway in animals, now joined by a confounded but positive human trial in diabetic neuropathy); general analgesic/anti-inflammatory activity (a distinct quinazoline alkaloid, and separately an opioid-linked mechanism, animal-only); bone density and formation (polyphenols, ERK/AKT/CREB, animal-only); hepatic protection and regeneration (antioxidant, Nrf2/glutathione, animal-only); rasayana-style antioxidant activity (real for the ethanolic extract, weaker for the traditional water infusion, animal/in vitro).
• Genuinely contradictory to the “energising” narrative: the one dedicated CNS pharmacology study, which found a depressant, not stimulant, behavioural profile.
• Now entering human trials, unusually for this plant: a positive but herb-combination-confounded RCT in diabetic neuropathy, and a registered single-agent protocol for frozen shoulder awaiting results.

Most of the claims on this page have never been tested in a human trial, and all of the mechanistic work is animal or in vitro. The exception is genuinely new: as of 2022 and 2025 respectively, this plant has its first completed human trial (confounded by a co-administered herb) and its first registered single-agent trial protocol, both in this page’s claim territory rather than in the weight-loss claim covered elsewhere in this leg. The traditional root-and-neurological, root-and-joint, and convalescent-tonic indications now have real, independently-replicated, non-adrenergic modern pharmacology behind them, and are starting — slowly, and not yet cleanly — to acquire human evidence too. That is a materially different, and more interesting, situation than the “it’s all just the stimulant” shorthand would suggest.

Evidence Ledger for This Page

1. Animal, mechanistic, recent, alkaloid-independent — the strongest tier here. Neuropathic pain reduction via betaine and NMDA-pathway modulation (root extract, 2024); bone formation and prevention of ovariectomy-induced bone loss via polyphenols (root and leaf extract, 2022).
2. Animal, replicated across independent labs and countries. General analgesic/anti-inflammatory activity — Bangladesh, India, Brazil, Burkina Faso — through at least three distinct proposed mechanisms.
3. Animal, single-herb (not formula). Cartilage protection in collagenase-induced osteoarthritis, dosed as an individual herb powder alongside five others tested the same way.
4. Animal, solvent-dependent. Rasayana-framed antioxidant activity — strong for the ethanolic extract, much weaker for the traditional water infusion.
5. Animal, two mechanisms, two solvents. Hepatoprotection against alcohol toxicity (ethanolic root extract, Nrf2/glutathione mechanism) and liver regeneration after injury (aqueous leaf extract).
6. Genuine contradiction, reported rather than hidden. The only dedicated CNS pharmacology study found a sedative-type, not stimulant, behavioural profile at high dose.
7. Human, positive, but formula-confounded. A 90-patient randomised placebo-controlled trial found a Phyllanthus niruri + Sida cordifolia combination reduced diabetic neuropathy symptom scores — real human evidence in the right claim territory, not attributable to Sida cordifolia alone.
8. Human, single-agent, protocol stage. A registered, recruiting trial of Sida cordifolia oil alone (nasal administration) for frozen shoulder; no results published yet.
9. Absent, not refuted. Any single-agent human trial result for any claim on this page — bone density, liver protection, antioxidant/rasayana benefit, general analgesia, or subjective energy.
10. Not cleared by this page. The “energising adaptogen” marketing claim, which remains, on current evidence, the stimulant-alkaloid story the hub already covers.

Key Research Papers

1. CNS pharmacological effects of the hydroalcoholic extract of Sida cordifolia L. leaves. Franco CI et al., Journal of Ethnopharmacology, 2005. The sedative-type finding. PubMed search
2. Sida cordifolia L. attenuates behavioral hypersensitivity by interfering with KIF17-NR2B signaling in rat model of neuropathic pain. Tiwari V, Hemalatha S, Journal of Ethnopharmacology, 2024. PubMed search
3. A randomized placebo-compared study on the efficacy of classical ayurvedic pharmaceutical form versus aqueous alcoholic extracts of Phyllanthus niruri Linn. Plus Sida cordifolia Linn. in patients of diabetic sensory polyneuropathy. Patel MV et al., Journal of Ayurveda and Integrated Medicine, 2022. The first completed human trial, combination-confounded. PubMed search
4. Evaluation of the Comparative Efficacy of Honey Thermal Microcautery, Standard Physiotherapy, and Sida cordifolia Oil via Nasal Administration in the Management of Frozen Shoulder: Protocol for a Randomized Controlled Trial. Pathania S et al., JMIR Research Protocols, 2025. The first single-agent human trial protocol. PubMed search
5. Anti-inflammatory and analgesic alkaloid from Sida cordifolia linn. Sutradhar RK et al., Pakistan Journal of Pharmaceutical Sciences, 2007. PubMed search
6. Analgesic, antiinflammatory and hypoglycaemic activities of Sida cordifolia. Kanth VR, Diwan PV, Phytotherapy Research, 1999. PubMed search
7. Sida cordifolia leaf extract reduces the orofacial nociceptive response in mice. Bonjardim LR et al., Phytotherapy Research, 2011. The naloxone-sensitive, partly opioid-linked result. PubMed search
8. Toxicity assessment and analgesic activity investigation of aqueous acetone extracts of Sida acuta… and Sida cordifolia…, medicinal plants of Burkina Faso. Konaté K et al., BMC Complementary and Alternative Medicine, 2012. Includes the LD50 data. PubMed search
9. Influence of six medicinal herbs on collagenase-induced osteoarthritis in rats. Nirmal P et al., American Journal of Chinese Medicine, 2013. Single-herb dosing, not a formula. PubMed search
10. Ethanolic extract from the root and leaf of Sida cordifolia promotes osteoblast activity and prevents ovariectomy-induced bone loss in mice. Patel K et al., Phytomedicine, 2022. The bone-mechanism reframing of “strength.” PubMed search
11. Screening of antioxidant activity of three Indian medicinal plants, traditionally used for the management of neurodegenerative diseases. Auddy B et al., Journal of Ethnopharmacology, 2003. The rasayana claim tested directly, with the solvent gap. PubMed search
12. Amelioration of alcohol-induced hepatotoxicity by the administration of ethanolic extract of Sida cordifolia Linn. Rejitha S et al., British Journal of Nutrition, 2012. PubMed search
13. Nrf2-mediated antioxidant response by ethanolic extract of Sida cordifolia provides protection against alcohol-induced oxidative stress in liver by upregulation of glutathione metabolism. Rejitha S et al., Redox Report, 2015. PubMed search
14. Effect of the aqueous extract of Sida cordifolia on liver regeneration after partial hepatectomy. Silva RL et al., Acta Cirúrgica Brasileira, 2006. The aqueous-extract, tradition-matched result. PubMed search

Connections

• All Herbs
• Sida Cordifolia (Bala) — Main Page — the rejuvenative-claim critique this page builds on.
• Sida Cordifolia Benefits Hub
• Respiratory and Bronchodilator Use — the plant’s other quinazoline-alkaloid claim.
• Wound Healing and Topical Use
• Weight-Loss Trials and Marketing
• Ashwagandha — the genuinely calming, trial-supported adaptogen bala is marketed beside.
• Neurology
• Rheumatology
• Gastroenterology — liver-disease context for the hepatic findings above.
• Minerals

Back to Table of Contents